newsfilter
← Latest News
ClinicalTrials.gov·

Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients - NCT04520451

The proportion of patients who achieve complete remission at Week 12 with no glucocorticoid use at Week 4 for the Experimental Arm and Week 12 for the Active Comparator Arm., Serum IgG4 concentrations, IgG4-RD Responder Index